Answers are grounded in this paper and cite their sources.
Abstract β-(1→3,1→6)-Glucan is valued for its immunomodulatory activity, but conventional production via fungal cell wall extraction suffers from complex procedures and low yields. Here, the mangrove-derived strain Aureobasidium melanogenum BZ-11 was engineered by sequentially disrupting the melanin and pullulan biosynthetic pathways, generating the mutant strain BZΔPΔA capable of producing pigment-free, pullulan-free extracellular β-glucan. β-Glucan featured a β-(1→3,1→6)-linked structure with a high molecular weight of (1.33 ± 0.24) × 106 g/mol and a high degree of branching of 57%, along with favorable storage and processing stability. In a 10 L fermentation, BZΔPΔA achieved an extracellular β-glucan titer of 20.33 ± 1.42 g/L. Direct ethanol precipitation and lyophilization from the culture supernatant yielded 94.83% β-glucan purity and 97.78% recovery, enabling simple purification without harsh extraction. This work establishes a scalable and efficient platform for producing structurally defined extracellular β-(1→3,1→6)-glucan, with strong potential for applications in functional foods, pharmaceuticals, and biomedical products.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: